2023年度妇科恶性肿瘤治疗进展及展望

冯征; 郭勤浩; 朱俊; 吴小华; 温灏

doi:10.19401/j.cnki.1007-3639.2024.04.002

您当前的位置：

首页 >

文章列表页 >

2023年度妇科恶性肿瘤治疗进展及展望

专家述评 | 更新时间：2025-12-31

- 2023年度妇科恶性肿瘤治疗进展及展望
- Progress in treatment of gynecological cancer in 2023
- 中国癌症杂志 2024年34卷第4期页码：340-360
- 作者机构：
  
  复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
  
  [ "冯征（ORCID: 0000-0003-2561-3869），主治医师。" ]
  [ "吴小华，医学博士，主任医师，教授，博士研究生导师。现任复旦大学附属肿瘤医院妇瘤科主任、妇科肿瘤多学科综合治疗组首席专家，上海市优秀学科带头人，上海市医学领军人才。现任中国抗癌协会卵巢癌专业委员会主任委员、中国初级卫生保健基金会妇科专业委员会主任委员、中国临床肿瘤学会理事、上海市抗癌协会常务理事、中国抗癌协会妇科肿瘤专业委员会前任主任委员及上海市抗癌协会妇科肿瘤专业委员会前任主任委员。曾任国际妇科癌症学会教育委员会委员、亚太地区理事候选人、美国妇科肿瘤学会国际委员会委员、美国西北大学Feinberg医学院妇产科学系兼职教授等。目前还担任International Journal of Gynecological Cancer、Cancer Medicine、Journal of Gynecological Oncology等英文杂志和《中华妇产科杂志》《中华解剖与临床杂志》《中国癌症杂志》等中文杂志编委，美国国家综合癌症网络（National Comprehensive Cancer Network，NCCN）妇科肿瘤临床指南国际审阅专家。" ]
  [ "温灏，医学博士、副主任医师、硕士研究生导师。现任复旦大学附属肿瘤医院肿瘤妇科行政副主任，复旦大学附属肿瘤医院福建医院妇科肿瘤诊治中心常务副主任。兼任中国抗癌协会子宫体肿瘤专业委员会常务委员、中国抗癌协会肿瘤标志专业委员会妇科肿瘤标志物专家学组副组长、中国抗癌协会青年理事会理事、中国初级卫生保健基金会妇科专委会常务委员及秘书长、中国妇幼健康研究会妇产科精准医疗专业委员会委员、中国优生优育协会妇产专业委员会委员、中国医药教育协会肿瘤药物临床研究评价专委会委员、中国老年保健协会肿瘤防治和临床研究管理专业委员会委员、上海市抗癌协会妇科肿瘤专业委员会候任主任委员、上海市抗癌协会青年理事会理事、上海市抗癌协会肿瘤药物临床研究专委会委员、上海研究型医院学会妇产科转化医学研究与发展专委会副主任委员、上海市医学会妇科肿瘤分会卵巢癌学组副组长。担任Gynecology and Pelvic Medicine、《现代妇产科进展》《肿瘤药学》《肿瘤综合治疗电子杂志》等杂志编委，《中国癌症杂志》青年编委、《临床肿瘤学杂志（JCO）》中文版妇瘤专刊青年编委。" ]
- 基金信息：
  
  上海市自然科学基金(21ZR1415000)
- DOI：10.19401/j.cnki.1007-3639.2024.04.002
  中图分类号： R737.3
- 收稿：2024-03-12，
  
  修回：2024-04-06，
  
  纸质出版：2024-04-30
- 稿件说明：
移动端阅览
冯征, 郭勤浩, 朱俊, 等. 2023年度妇科恶性肿瘤治疗进展及展望[J]. 中国癌症杂志, 2024,34(4):340-360.

Zheng FENG, Qinhao GUO, Jun ZHU, et al. Progress in treatment of gynecological cancer in 2023[J]. China Oncology, 2024, 34(4): 340-360.
冯征, 郭勤浩, 朱俊, 等. 2023年度妇科恶性肿瘤治疗进展及展望[J]. 中国癌症杂志, 2024,34(4):340-360. DOI： 10.19401/j.cnki.1007-3639.2024.04.002.

Zheng FENG, Qinhao GUO, Jun ZHU, et al. Progress in treatment of gynecological cancer in 2023[J]. China Oncology, 2024, 34(4): 340-360. DOI： 10.19401/j.cnki.1007-3639.2024.04.002.

摘要

对比中国与全球情况可知，中国癌症发病率与世界平均水平接近，但死亡率与全球平均水平有差异。中国妇科恶性肿瘤负担日益加重，城乡差异较大，地区分布不均衡，癌症防控形势严峻。近年来，新技术、新药物[如免疫检查点抑制剂（immune checkpoint inhibitor，ICI）、抗体-药物偶联物（antibody-drug conjugate，ADC）等]陆续进入临床，为妇科恶性肿瘤的治疗带来新希望。本文对2023年度妇科恶性肿瘤的重大研究进展进行梳理，其中，在宫颈癌治疗方面，本文回顾了标准治疗模式革新、晚期复发转移性宫颈癌后线治疗的相关进展（ENGOT-cx11/GOG-3047/KEYNOTE-A18、KEYNOTE-826研究等）；在卵巢癌治疗方面，本文总结了PARP抑制剂及免疫治疗、新诊断卵巢癌一线治疗、复发性卵巢癌治疗的最新进展（FLAMES、ANITA/ENGOT-Ov41/GEICO 69-O、NRG-GY004研究等）；而在子宫内膜癌治疗方面，本文按照局部晚期子宫内膜癌治疗（GOG 258、Lunchbox研究等）、晚期/复发转移性子宫内膜癌治疗方面的进展（如ENGOT-EN6-NSGO/GOG-3031/RUBY研究等）进行综述，并对后线靶向治疗和免疫治疗探索进行总结（如KEYNOTE-775、ADAGIO等研究）。本文从上述方面对妇科肿瘤2023年度的进展进行述评，旨在为临床实践及临床研究的开展提供参考。

Abstract

Compared with the global situation

it can be found that the cancer incidence in China is close to the world average level

but the mortality rate has difference compared with the global average level. The burden of gynecological cancers in China is increasing

with large differences between urban and rural areas and uneven regional distribution. Therefore

the situation of cancer prevention and control is still challenging. In recent years

new technologies and drugs

such as immune checkpoint inhibitors (ICIs) and antibody-drug conjugate (ADC)

have been introduced into clinical practice

bringing new hope for the treatment of gynecological cancers. This article reviewed the major research progress of gynecological cancers in 2023. Among them

in terms of the progress of treatment for cervical cancer

we reviewed the innovation of standard treatment mode and the related progress of post-line treatment for advanced recurrent and metastatic cervical cancer (clinical research such as ENGOT-cx11/GOG-3047/KEYNOTE-A18

KEYNOTE-826). In terms of treatment for ovarian cancer

this review summarized the latest progress of PARP inhibitors

immunotherapy

first-line treatment of newly diagnosed ovarian cancer and treatment of recurrent ovarian cancer (FLAMES

ANITA/ENGOT-Ov41/GEICO 69-O

NRG-GY004

etc.). In terms of treatment for endometrial cancer

this study reviewed the progress in the treatment of locally advanced endometrial cancer (GOG 258

Lunchbox clinical research

etc.) and advanced/recurrent metastatic endometrial cancer (ENGOT-EN6-NSGO/GOG-3031/RUBY research

etc.)

and summarized the exploration of back-line targeted immunotherapy (such as KEYNOTE-775

ADAGIO and other clinical studies). This study combed the progress of gynecological tumors in 2023 from the above aspects

aiming at providing reference for clinical practice and clinical research.

关键词

Keywords

references

QI J L , LI M L , WANG L J , et al . National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data [J ] . Lancet Public Health , 2023 , 8 ( 12 ): e943 - e955 . DOI: 10.1016/S2468-2667(23)00211-6 http://doi.org/10.1016/S2468-2667(23)00211-6

ZHENG R S , CHEN R , HAN B F , et al . Cancer incidence and mortality in China, 2022 [J ] . Chin J Oncol , 2024 , 46 ( 3 ): 221 - 231 .

ZHENG R S , ZHANG S W , ZENG H M , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Cent , 2022 , 2 ( 1 ): 1 - 9 .

PLANTE M , KWON J S , FERGUSON S , et al . An international randomized phase Ⅲ trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): a Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE) [J ] . J Clin Oncol , 2023 , 41 ( 17_suppl ): LBA5511 .

LORUSSO D , XIANG Y , HASEGAWA K , et al . Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: a randomized, double-blind, phase Ⅲ ENGOT-cx11/GOG-3047/KEYNOTE-A18 study [J ] . Ann Oncol , 2023 , 34 : S1279 - S1280 .

MONK B , TOITA T , WU X H , et al . Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial [C ] // Oral Abstracts. BMJ Publishing Group Ltd , 2022 .

MCCORMACK M , GALLARDO RINCÓN D , EMINOWICZ G , et al . A randomised phase Ⅲ trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial [J ] . Ann Oncol , 2023 , 34 : S1276 .

MILESHKIN L R , MOORE K N , BARNES E H , et al . Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial [J ] . Lancet Oncol , 2023 , 24 ( 5 ): 468 - 482 . DOI: 10.1016/S1470-2045(23)00147-X http://doi.org/10.1016/S1470-2045(23)00147-X

MONK B J , COLOMBO N , TEWARI K S , et al . First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826 [J ] . J Clin Oncol , 2023 , 41 ( 36 ): 5505 - 5511 .

WU X , XIA L , ZHANG K , et al . Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer [J ] . Ann Oncol , 2023 , 34 : S1284 - S1285 .

XIA L F , ZHOU Q , GAO Y N , et al . A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma [J ] . Nat Commun , 2022 , 13 ( 1 ): 7581 . DOI: 10.1038/s41467-022-35133-4 http://doi.org/10.1038/s41467-022-35133-4

LEE J Y , WU L , BOONYAPIPAT S , et al . 744MO AdvanTIG-202: phase Ⅱ randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC) [J ] . Ann Oncol , 2023 , 34 : S509 - S510 .

VERGOTE I B , GONZALEZ MARTIN A , FUJIWARA K , et al . LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase Ⅲ study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer [J ] . Ann Oncol , 2023 , 34 : S1276 - S1277 .

赵海云 , 吴小华 . 免疫治疗在卵巢癌中的应用研究进展 [J ] . 中国癌症杂志 , 2020 , 30 ( 7 ): 538 - 545 .

ZHAO H Y , WU X H . Research progress of immunotherapy in ovarian cancer [J ] . China Oncol , 2020 , 30 ( 7 ): 538 - 545 .

中国抗癌协会肿瘤内分泌专业委员会 . 妇科恶性肿瘤免疫治疗中国专家共识(2023年版) [J ] . 中国癌症杂志 , 2023 , 33 ( 10 ): 954 - 968 . DOI: 10.19401/j.cnki.1007-3639.2023.10.008 http://doi.org/10.19401/j.cnki.1007-3639.2023.10.008

Society of Onco-Endocrinology of Chinese Anti-Cancer Association . Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition) [J ] . China Oncol , 2023 , 33 ( 10 ): 954 - 968 .

WU X , LIU J , WANG X , et al . LBA36 Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): a randomized, double-blind, placebo-controlled, phase Ⅲ trial [J ] . Ann Oncol , 2023 , 34 : S1277 - S1278 .

MOORE K N , BOOKMAN M , SEHOULI J , et al . Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage Ⅲ or Ⅳ ovarian cancer: placebo-controlled randomized phase Ⅲ trial (IMagyn050/GOG 3015/ENGOT-OV39) [J ] . J Clin Oncol , 2021 , 39 ( 17 ): 1842 - 1855 .

PIGNATA S , BOOKMAN M , SEHOULI J , et al . Overall survival and patient-reported outcome results from the placebo-controlled randomized phase Ⅲ IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage Ⅲ/Ⅳ ovarian cancer [J ] . Gynecol Oncol , 2023 , 177 : 20 - 31 .

MONK B J , COLOMBO N , OZA A M , et al . Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial [J ] . Lancet Oncol , 2021 , 22 ( 9 ): 1275 - 1289 . DOI: 10.1016/S1470-2045(21)00342-9 http://doi.org/10.1016/S1470-2045(21)00342-9

DOMCHEK S M , POSTEL-VINAY S , IM S A , et al . Olaparib and durvalumab in patients with germline BRCA -mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study [J ] . Lancet Oncol , 2020 , 21 ( 9 ): 1155 - 1164 .

HARTER P , TRILLSCH F , OKAMOTO A , et al . Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA 1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase Ⅲ DUO-O trial [J ] . J Clin Oncol , 2023 , 41 ( 17_suppl ): LBA5506 .

GONZALEZ MARTIN A , RUBIO PEREZ M J , HEITZ F , et al . Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase Ⅲ trial [J ] . Ann Oncol , 2023 , 34 : S1278 - S1279 .

GONZALEZ MARTIN A , SANCHEZ LORENZO L , COLOMBO N , et al . A phase Ⅲ, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA trial [J ] . Int J Gynecol Cancer , 2021 , 31 ( 4 ): 617 - 622 .

LIU J F , BRADY M , MATULONIS U A , et al . Overall survival (OS) outcomes from NRG-GY004, a phase Ⅲ study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) [J ] . Ann Oncol , 2023 , 34 : S1285 .

LIU J F , BARRY W T , BIRRER M , et al . Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study [J ] . Lancet Oncol , 2014 , 15 ( 11 ): 1207 - 1214 . DOI: 10.1016/S1470-2045(14)70391-2 http://doi.org/10.1016/S1470-2045(14)70391-2

LEE J M , MILLER A , ROSE P , et al . 746MO Randomized phase Ⅱ trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023) [J ] . Ann Oncol , 2023 , 34 : S511 .

KURTZ J E , PUJADE-LAURAINE E , OAKNIN A , et al . Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase Ⅲ ATALANTE/ENGOT-ov29 trial [J ] . J Clin Oncol , 2023 , 41 ( 30 ): 4768 - 4778 .

PUJADE-LAURAINE E , FUJIWARA K , LEDERMANN J A , et al . Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study [J ] . Lancet Oncol , 2021 , 22 ( 7 ): 1034 - 1046 .

COLEMAN R , OAKNIN A , PIGNATA S , et al . Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: evaluation of sequence of therapy on anti-tumor activity in the SORAYA study (002) [J ] . Gynecol Oncol , 2023 , 176 : S3 .

MATULONIS U A , LORUSSO D , OAKNIN A , et al . Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study [J ] . J Clin Oncol , 2023 , 41 ( 13 ): 2436 - 2445 .

MOORE K N , ANGELERGUES A , KONECNY G E , et al . Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer [J ] . N Engl J Med , 2023 , 389 ( 23 ): 2162 - 2174 .

OMAR N , YAN B , SALTO-TELLEZ M . HER2: an emerging biomarker in non-breast and non-gastric cancers [J ] . Pathogenesis , 2015 , 2 ( 3 ): 1 - 9 .

YAN M , SCHWAEDERLE M , ARGUELLO D , et al . HER2 expression status in diverse cancers: review of results from 37 992 patients [J ] . Cancer Metastasis Rev , 2015 , 34 ( 1 ): 157 - 164 .

BUZA N , ENGLISH D P , SANTIN A D , et al . Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice [J ] . Mod Pathol , 2013 , 26 ( 12 ): 1605 - 1612 .

IQBAL N , IQBAL N . Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications [J ] . Mol Biol Int , 2014 , 2014 : 852748 .

MERIC-BERNSTAM F , HURWITZ H , RAGHAV K P S , et al . Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study [J ] . Lancet Oncol , 2019 , 20 ( 4 ): 518 - 530 .

MERIC-BERNSTAM F , MAKKER V , OAKNIN A , et al . Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase Ⅱ trial [J ] . J Clin Oncol , 2024 , 42 ( 1 ): 47 - 58 .

AREND R C , MONK B J , SHAPIRA-FROMMER R , et al . Ofranergene obadenovec (ofra-vec, VB-111) with weekly paclitaxel for platinum-resistant ovarian cancer: randomized controlled phase Ⅲ trial (OVAL study/GOG 3018) [J ] . J Clin Oncol , 2024 , 42 ( 2 ): 170 - 179 .

PUJADE-LAURAINE E , HILPERT F , WEBER B , et al . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase Ⅲ trial [J ] . J Clin Oncol , 2014 , 32 ( 13 ): 1302 - 1308 .

POVEDA A M , SELLE F , HILPERT F , et al . Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase Ⅲ AURELIA trial [J ] . J Clin Oncol , 2015 , 33 ( 32 ): 3836 - 3838 .

BEREK J S , MATIAS-GUIU X , CREUTZBERG C , et al . FIGO staging of endometrial cancer: 2023 [J ] . Int J Gynaecol Obstet , 2023 , 162 ( 2 ): 383 - 394 .

MATEI D , FILIACI V , RANDALL M E , et al . Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer [J ] . N Engl J Med , 2019 , 380 ( 24 ): 2317 - 2326 .

DE BOER S M , POWELL M E , MILESHKIN L , et al . Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial [J ] . Lancet Oncol , 2018 , 19 ( 3 ): 295 - 309 . DOI: S1470-2045(18)30079-2 http://doi.org/S1470-2045(18)30079-2

PIGNATA S , SCAMBIA G , SCHETTINO C , et al . Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial [J ] . Lancet Oncol , 2023 , 24 ( 3 ): 286 - 296 . DOI: 10.1016/S1470-2045(23)00016-5 http://doi.org/10.1016/S1470-2045(23)00016-5

ESKANDER R N , SILL M W , BEFFA L , et al . Pembrolizumab plus chemotherapy in advanced endometrial cancer [J ] . N Engl J Med , 2023 , 388 ( 23 ): 2159 - 2170 .

MIRZA M R , CHASE D M , SLOMOVITZ B M , et al . Dostarlimab for primary advanced or recurrent endometrial cancer [J ] . N Engl J Med , 2023 , 388 ( 23 ): 2145 - 2158 .

WESTIN S N , MOORE K , CHON H S , et al . Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase Ⅲ DUO-E trial [J ] . J Clin Oncol , 2024 , 42 ( 3 ): 283 - 299 .

COLOMBO N , HARANO K , HUDSON E , et al . Phase Ⅲ double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma [J ] . Ann Oncol , 2023 , 34 : S1281 - S1282 .

POWELL M A , HIETANEN S , COLEMAN R L , et al . Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) [J ] . J Clin Oncol , 2023 , 41 ( 16_suppl ): 5503 .

MIRZA M R , SHARMA S , HERRSTEDT J , et al . Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression-free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial [J ] . Ann Oncol , 2023 , 34 : S507 .

ESKANDER R , SILL M , BEFFA L , et al . Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: the phase 3, NRG GY018 study (LBA 10) [J ] . Gynecol Oncol , 2023 , 176 : S42 - S43 .

ESKANDER R N , SILL M , MILLER A , et al . Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial [J ] . Ann Oncol , 2023 , 34 : S1284 .

JOLY LOBBEDEZ F , LEARY A , RAY-COQUARD I L , et al . Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: the GINECO randomized phase Ⅱb UTOLA trial [J ] . Ann Oncol , 2023 , 34 : S1283 - S1284 .

MAKKER V , COLOMBO N , CASADO HERRÁEZ A , et al . Lenvatinib plus pembrolizumab for advanced endometrial cancer [J ] . N Engl J Med , 2022 , 386 ( 5 ): 437 - 448 .

MAKKER V , COLOMBO N , CASADO HERRÁEZ A , et al . Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase Ⅲ study 309/KEYNOTE-775 [J ] . J Clin Oncol , 2023 , 41 ( 16 ): 2904 - 2910 .

O’MALLEY D M , BARIANI G M , CASSIER P A , et al . Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study [J ] . J Clin Oncol , 2022 , 40 ( 7 ): 752 - 761 .

吕巧英 , 刘伟 , 陈晓军 . 基于分子特征的子宫内膜癌术后辅助治疗的研究进展 [J ] . 中华妇产科杂志 , 2023 , 58 ( 6 ): 474 - 480 .

LÜQ Y , LIU W , CHEN X J . Research progress of postoperative adjuvant therapy for endometrial cancer based on molecular characteristics [J ] . Chin J Obstet Gynecol , 2023 , 58 ( 6 ): 474 - 480 .

LIU J , OZA A M , COLOMBO N , et al . ADAGIO: a phase Ⅱb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma [J ] . Int J Gynecol Cancer , 2022 , 32 ( 1 ): 89 - 92 .

LIU J , COLOMBO N , OZA A , et al . ADAGIO: a phase Ⅱb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma (039) [J ] . Gynecol Oncol , 2023 , 176 : S33 - S35 .

MERIC-BERNSTAM F , MAKKER V , OAKNIN A , et al . Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results [J ] . J Clin Oncol , 2023 , 41 ( 17_suppl ): LBA3000 .

郭勤浩 , 余敏 , 吴小华 . 2022年度妇科肿瘤诊治进展 [J ] . 中国癌症杂志 , 2023 , 33 ( 1 ): 14 - 24 . DOI: 10.19401/j.cnki.1007-3639.2023.01.002 http://doi.org/10.19401/j.cnki.1007-3639.2023.01.002

GUO Qinhao , YU Min , WU Xiaohua . Progress in diagnosis and treatment of gynecological tumors in 2022 [J ] . China Oncology , 2023 , 33 ( 1 ): 14 - 24 . DOI: 10.19401/j.cnki.1007-3639.2023.01.002 http://doi.org/10.19401/j.cnki.1007-3639.2023.01.002

浏览量

2464

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

2023年ESMO妇科肿瘤治疗最新进展及展望

2022年度妇科肿瘤诊治进展

2025 年度妇科恶性肿瘤年度进展盘点

妇科恶性肿瘤术后激素替代治疗的研究进展

2020年度妇科恶性肿瘤最新研究进展及展望